US Pharma MarketingJ&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
The company said that JNJ-4804, a combination of the blockbuster drugs Tremfya and Simponi, missed its primary endpoints in studies for Crohn’s disease and ulcerative colitis. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials.
The company said that JNJ-4804, a combination of the blockbuster drugs Tremfya ...
Source: Endpoints News